featured-image

( MENAFN - GlobeNewsWire - Nasdaq) BROSSARD, Quebec, Oct. 25, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the“Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (AI) technologies, announces the closing, today, of a non-brokered private placement of 5,228,668 units (each a“Unit”) issued at a price of $0.

30 per Unit, for gross proceeds of $1,568,600.40 (“Private Placement”). Together with the closing of the private placement of $2,499,999.



90, announced on September 20, 2024, the Corporation has raised $4,068,600.30 in additional financing. Each Unit consists of: As part of the closing of the Private Placement, 5,228,668 Warrants have been issued to the subscribers.

Each Warrant can be exercised to purchase one Share at a price of $0.40 per Share for a period of 18 months ending April 25, 2026. In connection with the closing of the Private Placement, the Corporation (i) paid cash commissions amounting to $18,207 and (ii) issued an aggregate number of 60,690 finder's warrants to three qualified firms acting at arm's length to the Corporation.

Each finder's warrant entitles the holder to purchase one Share at an exercise price of $0.40 per Share for a period of 18 months ending April 25, 2026. The net proceeds from the Private Placement will be used to fund product development and commercialization of AI-based screening services, regulatory affairs as well as gen.

Back to Health Page